Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia
Launched by CAIRO UNIVERSITY · Jan 28, 2015
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
50 pregnant females were divided in two groups, twenty five as a control group and twenty five as high risk group; they were subjected to uterine artery Doppler, measurement of maternal serum (pp-13) and detection of (MTHFR) gene polymorphisms in first trimester at 11 to 14 weeks of gestation, all pregnancies were followed until 40 weeks for development of pre-eclampsia
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • pregnant women at 11 to 14 weeks of gestation
- Exclusion Criteria:
- • fetal anomalies other medical diseases as diabetes mellitus, renal or liver diseases
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Ahmed Maged
Principal Investigator
Kasr Alainy medical school
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials